Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. [electronic resource]
Producer: 20141229Description: 421 p. digitalISSN:- 1435-1803
- Angiotensin-Converting Enzyme Inhibitors -- pharmacology
- Animals
- Cardiotonic Agents -- pharmacology
- Cell Communication
- Cells, Cultured
- Disease Models, Animal
- Drug Therapy, Combination
- Enzyme Activation
- Enzyme Activators -- pharmacology
- Extracellular Matrix -- metabolism
- Fibrosis
- Guanylate Cyclase -- metabolism
- Heart Failure -- drug therapy
- Hemodynamics -- drug effects
- Humans
- Male
- Mice
- Mitochondria, Heart -- drug effects
- Myocardial Contraction -- drug effects
- Myocardial Infarction -- complications
- Myocytes, Cardiac -- drug effects
- Myofibroblasts -- drug effects
- Nitric Oxide -- metabolism
- Nitric Oxide Synthase Type III -- metabolism
- Oxidative Stress -- drug effects
- Ramipril -- pharmacology
- Rats, Wistar
- Receptors, Cytoplasmic and Nuclear -- metabolism
- Soluble Guanylyl Cyclase
- Sulfonamides -- pharmacology
- Superoxides -- metabolism
- Time Factors
- Ventricular Function, Left -- drug effects
- Ventricular Remodeling -- drug effects
- ortho-Aminobenzoates -- pharmacology
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.